Valuation: Moderna, Inc.

Market Cap 22.46B 19.45B 18.13B 16.68B 31.48B 2,136B 31.84B 213B 83.63B 1,069B 84.35B 82.49B 3,539B P/E 2026 *
-6.56x
P/E 2027 * -11.4x
Enterprise Value 18.81B 16.29B 15.19B 13.97B 26.37B 1,789B 26.67B 178B 70.05B 895B 70.65B 69.1B 2,964B EV / Sales 2026 *
8.93x
EV / Sales 2027 * 8.34x
Free-Float
92.75%
Yield 2026 *
-
Yield 2027 * -
1 day-0.16%
1 week-2.71%
Current month+2.79%
1 month-31.11%
3 months+15.49%
6 months+37.41%
Current year+91.08%
1 week 52.66
Extreme 52.6601
59.49
1 month 52.66
Extreme 52.6601
82.9
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2011
Director of Finance/CFO 49 05/09/2022
President 50 31/10/2024
Director TitleAgeSince
Chairman 63 31/01/2012
Director/Board Member 54 28/02/2011
Director/Board Member 69 10/12/2019
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Fiscal year

Chairperson

160,008 0.0403%
08/07/26 Free

Director

14,766 0.0037%
05/07/26 Free

Executive/Senior Manager

57,022 0.0144%
Change 5-day change 1-year change 3-year change Capi.($)
+0.08%-2.71%+110.97%-44.32% 22.46B
+0.13%+4.92%+39.55%-0.01% 76.75B
-0.35%+5.21%+24.89%+185.66% 50.46B
+1.02%+0.81%-7.73%+21.83% 48.5B
+1.30%+3.46%-50.91%-49.51% 44.14B
-0.46%-0.73%+59.59%-23.89% 30.53B
-2.08%-3.78%+52.40%+82.31% 24.28B
+0.72%+3.23%-7.24%+213.08% 20.04B
+0.57%-6.43%+64.02%+118.48% 16.14B
+2.23%+1.28%+85.65%+168.70% 16.03B
Average +0.30%-1.02%+37.12%+67.23% 34.93B
Weighted average by Cap. +0.26%+0.33%+27.23%+49.81%

Financials

2026 *2027 *
Net sales 2.11B 1.82B 1.7B 1.56B 2.95B 200B 2.98B 19.98B 7.84B 100B 7.91B 7.73B 332B 2.42B 2.1B 1.96B 1.8B 3.4B 230B 3.43B 22.99B 9.02B 115B 9.1B 8.9B 382B
Net income -3.38B -2.93B -2.73B -2.51B -4.74B -321B -4.79B -32.06B -12.58B -161B -12.69B -12.41B -532B -1.93B -1.67B -1.56B -1.43B -2.7B -183B -2.73B -18.29B -7.18B -91.71B -7.24B -7.08B -304B
Net Debt -3.65B -3.16B -2.94B -2.71B -5.11B -347B -5.17B -34.6B -13.58B -174B -13.7B -13.39B -575B -2.24B -1.94B -1.81B -1.67B -3.15B -213B -3.18B -21.3B -8.36B -107B -8.43B -8.24B -354B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
06/08/26 US$56.54 +0.51% 860,884
05/08/26 US$56.26 -1.29% 5,163,265
04/08/26 US$56.99 +3.36% 4,000,143
03/08/26 US$55.14 +0.58% 5,176,711
31/07/26 US$54.82 -5.35% 7,764,502
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
56.26USD
Average target price
50.84USD
Spread / Average Target
-9.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock